Navigation Links
Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
Date:4/7/2008

LA JOLLA, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) announced today that based on the U.S. Food and Drug Administration's ("FDA") review of its Phase 3 submission the Company can initiate its Phase 3 clinical program for its novel topical cream based non-steroidal anti-inflammatory drug ("NSAID"), Ketotransdel(TM). Transdel Pharmaceuticals is a specialty pharmaceutical company pursuing the development and commercialization of non-invasive topically administered medications.

Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals, stated, "I am pleased to announce that the FDA has reviewed our February 7, 2008 FDA submission and has stated that it is safe to proceed with the Phase 3 program. The FDA also noted that there are no clinical hold issues and provided comments regarding the registration requirements of our lead drug. We will continue our discussions with the FDA regarding the final product approval requirements." Dr. Singh continued, "Advancing into Phase 3 clinical studies for Ketotransdel marks a significant milestone for the Company. Our dedicated and committed team is focused on successfully advancing our topical drug to FDA approval."

Based on industry estimates, the market for NSAIDs and Cox-2 inhibitors exceeds $6 billion per year; more than 30 million people worldwide use NSAIDs daily. Due to the recognition of known risks associated with orally administered NSAIDs, including cardiovascular, gastrointestinal and other medical complications, and the decline in the use of Cox-2 inhibitors because of safety concerns, Transdel believes that there is a significant demand for topical pain management products such as Ketotransdel. Moreover, the Company expects that Ketotransdel, if approved by the FDA, could become the first topical NSAID cream product in the United States for acute pain management. The drug could address a significant unmet med
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
2. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
3. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
4. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
5. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
9. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
10. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
11. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of ... Chief Scientific Officer, will present at the Stem Cell ... Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... 2014 Summary Global Markets Direct,s, ,Arbor ... provides an overview of the Arbor Pharmaceuticals, LLC.,s ... provides comprehensive information on the current therapeutic developmental ... analysis at various stages, therapeutics assessment by drug ...
(Date:9/30/2014)... Sept. 30, 2014  According to their CEO, ... cancer clinical trials is going through a complete ... the work of the current clinical trial management ... ,next generation, clinical trials, which will ultimately drive ... The company has been recognized by the ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post explaining ... , Senior citizens can qualify for affordable term life ... who are over 50 years old. Some term life ... examination. , Term life insurance with a simplified issue ... Having life insurance during retirement is important for covering ...
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
(Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
(Date:10/1/2014)... Kennebunkport, Maine (PRWEB) October 01, 2014 ... autoimmune disorders in the U.S., according to figures from ... Autoimmune Related Diseases Association (AARDA), and many of them ... higher chance of having undiagnosed celiac disease. Gluten ... helping raise awareness of undiagnosed celiac disease by publishing ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... HealthDay Reporter , TUESDAY, Jan. 18 (HealthDay News) ... might have another use: clearing arterial blockages in the ... research involving 19 stroke patients, doctors say this experimental ... patients for whom other clot-removal methods didn,t work. ...
... health may contribute to a healthy respiratory system, according ... . A new study suggests that periodontal disease may ... obstructive pulmonary disease (COPD) and pneumonia. These infections, which ... inhaled into the lower respiratory tract, can be severely ...
... advise about alcohol consumption?" was recently published by Maurizio Ponz ... argues that the message of health benefits of moderate drinking ... the general population." His reasons included (1) many people ... of wine, beer or spirits, and alcohol metabolism may differ ...
... 18 (HealthDay News) -- Women with polycystic ovary syndrome (PCOS) ... many consumer products than other women, a new study suggests. ... products, food and drink packaging and even dental materials. PCOS, ... characterized by excessive production of male sex hormones (androgens). PCOS ...
... XX, 2010) Thea Friedman, M.D., associate scientist and ... Cancer Center at Hackensack University Medical Center was recently ... (NIH-NCI) RO1 research grant to improve allogeneic blood ... grant provides $2 million in funding over the next ...
... is available in French . Montreal, ... in biology at Universit du Qubec Montral (UQAM), supported ... Elsy Edouard, UQAM, Department of Biological Sciences and BIOMED ... B-cell acute lymphocytic leukemia, a disease that occurs most commonly ...
Cached Medicine News:Health News:Stents Show Promise in Treating Brain Blockages 2Health News:Stents Show Promise in Treating Brain Blockages 3Health News:Healthy gums may lead to healthy lungs 2Health News:Critique 029: What should we advise about alcohol consumption? A debate amongst scientists 2Health News:Ovarian Cyst Syndrome May Raise Health Risks from Plastics Chemical 2Health News:Oncology basic research director at John Theurer Cancer Center continues transplantation research 2Health News:Discovery of a gene associated with a leukemia mostly affecting children 2
Rees bayonet forceps, standard, 5-1/2", TC....
... Channel Implants, designed to accept ... surgeon with an excellent reconstructive ... and floor blowout defects. Each ... placement of one or more ...
Medpor Complete Orbit are designed to replace non load bearing bony structures in the orbital area....
... Medpor Inferior Orbital Rim implant can provide ... is designed to be trimmed to meet ... small flange allows it to rest on ... floor. This flange allows easier positioning of ...
Medicine Products: